Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD
Published: Thursday, Dec 07, 2017



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

Clinicians are still not sure how to best implement pertuzumab into the disease course, says Brufsky. The question is, he says, is extra pertuzumab necessary?

Brufsky says that a lot of clinicians will give upfront neoadjuvant therapy with pertuzumab, and then have to decide about additional doses.
 


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

Clinicians are still not sure how to best implement pertuzumab into the disease course, says Brufsky. The question is, he says, is extra pertuzumab necessary?

Brufsky says that a lot of clinicians will give upfront neoadjuvant therapy with pertuzumab, and then have to decide about additional doses.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x